Ramelteon (Rozerem) and butabarbital (Butisol) are both medications used to treat insomnia, but they belong to different drug classes. Ramelteon is a melatonin receptor agonist that helps regulate sleep by mimicking the natural hormone melatonin. It is taken orally, typically 30 minutes before bedtime, and is not a controlled substance, meaning it is not habit-forming. In contrast, butabarbital is a barbiturate, a class of medications known for their sedative effects, but it has been discontinued and is no longer available in the U.S. Butabarbital was a Schedule III controlled substance, indicating a potential for abuse and dependence. Ramelteon is available as a generic medication and is not known to cause withdrawal symptoms, while butabarbital could be habit-forming. Common side effects of ramelteon include dizziness and sleepiness, whereas butabarbital's side effects are not detailed due to its discontinuation. Additionally, ramelteon should not be taken with high-fat meals or certain medications like fluvoxamine, while butabarbital's interactions are less relevant given its unavailability.